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Abstract
Background: Induced sputum (IS) allows to measure mediators of asthmatic inflamma-
tion in bronchial secretions. NSAID-exacerbated respiratory disease (NERD) is recog-
nized as a distinct asthma phenotype, usually with a severe course, eosinophilic airway 
inflammation, and increased production of pro-inflammatory eicosanoids. A more in-
sightful analysis of NERD patients has shown this phenotype to be nonhomogeneous.
Objective: We aimed to identify possible subphenotypes in a cohort of NERD pa-
tients with the means of latent class analysis (LCA).
Methods: A total of 95 asthma patients with aspirin hypersensitivity underwent 
sputum induction. High-performance liquid chromatography or gas chromatography 
coupled with mass spectrometry was used to profile eicosanoids in induced sputum 
supernatant (ISS). Sixteen variables covering clinical characteristics, IS inflammatory 
cells, and eicosanoids were considered in the LCA.
Results: Three classes (subphenotypes) were distinguished within the NERD cohort. 
Class 1 subjects had mild-to-moderate asthma, an almost equal distribution of inflam-
matory cell patterns, the lowest concentrations of eicosanoids, and logLTE4/logPGE2 
ratio. Class 2 represented severe asthma with impaired lung function despite high 
doses of steroids. High sputum eosinophilia was in line with higher pro-inflammatory 
LTE4 in ISS and the highest logLTE4/logPGE2 ratio. Class 3 subjects had mild-to-mod-
erate asthma and were also characterized by eosinophilic airway inflammation, yet 
increased production of pro- (LTE4, PGD2 and 11-dehydro-TBX2) was balanced by 
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1  | INTRODUC TION
According to the current recommendations nonsteroidal anti-inflam-
matory drugs (NSAIDs)-exacerbated respiratory disease (abbrevi-
ated as NERD) is a proper term to describe the distinct phenotype of 
aspirin (acetyl salicylic acid; ASA) and other NSAIDs hypersensitivity, 
which involves upper and lower airway mucosa.1
It is characterized by eosinophilic inflammation of upper and lower 
airways, an onset in early adulthood and a predilection for females. 
Respiratory symptoms are exacerbated by intake of aspirin and other 
nonsteroidal anti-inflammatory drugs (NSAID’s).2 Diagnosis is confirmed 
by aspirin challenge tests.3 NERD usually has a severe course accompa-
nied by chronic rhinosinusitis with recurrent nasal polyps, often requir-
ing multiple sinus surgeries.2,4 Atopy is rather frequent in this population.
A recent meta-analysis has indicated that 7% of asthmatics 
are aspirin-sensitive but that the prevalence doubles in severe 
asthmatics.5 A more insightful analysis of individual patients has 
shown this group to be nonhomogeneous.6,7
There is a consensus on the nonallergic mechanism responsible 
for asthmatic attacks in NERD, involving abnormal metabolism of 
arachidonic acid (AA) by cyclooxygenase (COX) and lipoxygenase 
(LO) pathways.2 Following ingestion of NSAIDs, COX-1 inhibition 
decreases biosynthesis of PGE2 leading to enhanced or disinhibited 
synthesis of cysteinyl leukotrienes (cysLTs). CysLTs released from eo-
sinophils and mast cells cause abrupt onset moderate-to-severe bron-
choconstriction and sometimes extrapulmonary signs of facial edema 
and skin erythema.2 Transcellular metabolism of AA derivatives in the 
airway during multi-cellular interaction generates various eicosanoids 
able to regulate inflammation and functional responses. The broken 
balance between anti-inflammatory mediators known as lipoxins,8,9 
PGE2,
10,11 and potentially pro-inflammatory mediators such as cysLTs 
and PGD2
12 has been linked to both severe asthma and NERD.13
anti-inflammatory PGE2. The value of logLTE4/logPGE2 was between values calcu-
lated for classes 1 and 3, similarly to disease control and severity.
Conclusions: LCA revealed three distinct NERD subphenotypes. Our results support a 
more complex pathobiology of aspirin hypersensitivity. Considering NERD heterogeneity, 
the relationship between inflammatory pathways and clinical manifestations of asthma 
may lead to more individualized treatment in difficult to treat patients in the future.
K E Y W O R D S
eicosanoids, induced sputum, latent class analysis, NSAID-exacerbated respiratory disease, 
phenotype
G R A P H I C A L  A B S T R A C T
Heterogeneity of NERD phenotype reflects differences in inflammatory response measured by airway cells and eicosanoids. Identifying 
subphenotypes provides a more insightful perception and suggests a need for more individualized approach. In aspect of logLTE4/logPGE2 
ratio, latent class analysis assigned subject to different groups better than identification by disease severity or control emphasizing the 
heterogeneity in NERD subgroup.
Abbreviations: LTE4, Leukotriene E4; NERD, NSAID-exacerbated respiratory disease; PGE2, Prostaglandin E2
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The fundamental factors in NERD contributing to the underlying 
dysregulation of eicosanoid metabolism remain in a focus of active in-
vestigation, suggesting participation of both Th1 and Th2 cytokines.14 
More attention is paid to group 2 innate lymphoid cells (ILC2s), a lin-
eage negative lymphocyte population that produces type 2 cytokines 
in allergic diseases, which are activated by mediators like cysLTs and 
PGD2 overproduced in NERD.
15 Platelet-leukocyte aggregates are also 
thought to take part in cysLTs generation during reactions to aspirin.16
Asthma is now being defined in terms of phenotypes and en-
dotypes.17 Our everyday clinical practice supported by previous 
studies6,7 shows that NERD patients present a wide spectrum of dis-
ease course yet share common features as chronic rhinosinusitis and 
intolerance of aspirin and other COX-1 inhibitors. Primarily defined 
by a pharmacological intolerance of COX-1 inhibitors, this complex 
endophenotype of NERD does not show clear associations with 
clinical measurements or laboratory biomarkers of asthma. We hy-
pothesized that detailed characteristics, including measurement of 
inflammatory biomarkers in airway secretions, can provide a wider 




In total, 95 patients with NERD were enrolled to the study. NSAID 
hypersensitivity diagnosis was established before the study based 
on a typical history confirmed by oral or bronchial provocation test 
with aspirin.3 The asthma diagnosis was ascertained according to 
GINA 2018 update.19 Patients remained without any asthma exacer-
bations or respiratory tract infections during the 6 weeks preceding 
the study and received asthma medications as currently prescribed 
(excluding antileukotriene drugs). None of the subjects with NERD 
underwent aspirin desensitization. The patients gave informed con-
sent to participate in the study, and official approval for the study 
protocol from the Jagiellonian University Ethics Committee was ob-
tained (KBET/7/B/2010). Clinical characteristics of study subjects 
are presented in Table 1.
2.2 | Data collection
A structured questionnaire was used to collect demographic data 
and detailed medical history including information on exacerbations 
and respiratory tract infections. The current level of asthma sever-
ity was ascertained according to GINA 2018 update.19 Asthma con-
trol was assessed by using the Asthma Control Test (ACT). Standard 
spirometry and skin prick tests were performed. Blood eosinophilia 
and total IgE levels were measured.
Study subjects underwent sputum induction. Induced sputum 
was collected and processed according to ERS recommendations.20 
Induced sputum samples were investigated for sputum differential 
cell count and induced sputum supernatant concentrations of se-
lected eicosanoids.
Differential count of sputum-induced cells allowed for clas-
sification into inflammatory patterns: eosinophilic—defined as 
induced sputum eosinophilia above 2%; neutrophilic—defined 
by induced sputum neutrophilia above 50%, mixed cellular with 
sputum eosinophilia above 2% and neutrophilia above 50%; and 
paucigranulocytic—when no predominant inflammation pattern 
was present.20,21
The concentration of eicosanoids in induced sputum supernatant 
was measured by gas chromatography/mass spectrometry (GC-MS) 
for PGE2 and PGD2, and by high-performance liquid chromatogra-
phy/tandem mass spectrometry (HPLC-MS/MS) for 5-HETE, 12-
HETE, 15-HETE, LTB4, D4, E4, PGA2, and 11-dehydro-TBX2. These 
analytical method details were presented elsewhere.13
2.3 | Analytic strategy and selection of variables
Latent class analysis considering 16 variables covering clinical char-
acteristics such as sex, BMI, age at asthma onset, asthma control 
and severity, use of inhaled and/or oral steroids, history of asthma 
exacerbations, FEV1, blood eosinophil count, total serum IgE, atopy 
status determined by skin prick tests, induced sputum inflammatory 
cells and selected eicosanoids—PGD2, PGE2, and LTE4, was applied 
on the collected data set. Based on our previous studies on asthma 
heterogeneity, we included in the analysis lipid mediators which play 
a key role in aspirin hypersensitivity and have a pro-inflammatory 
(PGD2 and LTE4) or anti-inflammatory (PGE2) impact on airways.
7
We used LCA approach as a model-based clustering method 
of objects described mainly by polytomous variables supported 
by quantitative covariates. The latent class model seeks to strat-
ify the cross-classification table of observed (or "manifest") vari-
ables by an unobserved ("latent") unordered categorical variable 
that eliminates all confounding between the manifest variable. 
The main assumption of the LCA model is "conditional" or "local" 
independence, that is, conditional upon values of latent variable 
responses to all of the manifest variable are assumed to be statis-
tically independent. Covariates are included in our model through 
their effects on the prior probabilities of latent class membership. 
Our model allows individuals’ prior so vary depending upon their 
observed covariates.
The R package poLCA22 was used for estimating parameters of 
LCA models and for identification of the optimal model according 
to AIC (Akaike's information criterion) in a stepwise manner by the 
analysis of models with the number of classes starting from 1 to 4 
(for 5 classes model number of parameters estimated (96) exceeds 
number of observations (95)).
AIC is founded on information theory and deals with the trade-
off between the goodness-of-fit of the model and the complexity 
of the model. More information about AIC can be found in http://
en.wikip edia.org/wiki/Akaike_infor mation_crite rion. Each subject 
was allocated when the best model was determined.
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2.4 | Statistical analysis
Summary statistics were presented as mean, standard deviation, 
median, 25th and 75th percentiles and number in each category 
with percentage of total. We transformed mediator concentra-
tions to their logarithm or used Box-Cox transformation to nor-
malize the distributions before analysis. Normality was checked 
using the Shapiro-Wilk test. A general linear model (GLM) and a 
post hoc Tukey's test were applied to analyze the differences in 
mediator levels between latent classes. Categorical data were ana-
lyzed using the chi-square and Fisher exact tests. A P < .05 was 
considered statistically significant. All other statistical analyses 
were performed with the use of Dell Statistica (v.13) and Origin 
Pro(v.9.1).
3  | RESULTS
The clinical characteristics for the entire NERD cohort are pre-
sented in Table 1. The main characteristics of the respective classes 
are summarized below in Tables 2 and 3; and Figures 1 and 2.
Forty-three patients (45.3%) were allocated to class 1, which was 
defined as having “mild-to-moderate asthma course, with no lung 
impairment, low sputum eosinophilia and the lowest concentrations 
of mediators in induced sputum.” Patients in this class were predom-
inantly female 70%, with a mean age 46.5 ± 11.5y. This class was 
characterized by an almost equal prevalence of inflammatory pheno-
types based on induced sputum cell counts—that is 30% of subjects 
had eosinophilic, 30% neutrophilic, 30% paucigranulocytic, and 10% 
mixed eosinophilic and neutrophilic pattern. Sputum eosinophilia 
(median 1.1%) was significantly lower than in classes 2 (P = .004) and 
3 (P = .03). Asthma tended to be mild-to-moderate (63%), not rarely 
intermittent (19%), without lung function impairment (mean FEV1 
96% ±9.8%). None of the subjects had uncontrolled asthma (mean 
ACT score 23.4 ± 2.3). Patients scarcely experienced exacerbations 
(median 0 per year). Asthma control was achieved by administration 
of low doses (median 250 mcg of fluticasone daily) of inhaled cortico-
steroids (ICS). About 39.5% of asthmatics were atopic. The concen-
tration of LTE4 in ISS was lower compared with classes 2 (P = .003) 
and 3 (P < .001), while concentrations of PGD2, PGE2, and 11-dehy-
dro-TBX2 were lower than in class 3 (P < .001 for above mentioned).
Thirty-six subjects (37.9%) were assigned to class 2, which 
was defined by asthma with a severe course, poorly controlled, 
with airway obstruction, frequent exacerbations, eosinophilic 
airway inflammation, and increased pro-inflammatory mediators 
in induced sputum. Similarly to class 1, subjects were predomi-
nantly women (83%), with a mean age of 48.3 ± 13.3y. The in-
duced sputum inflammatory patterns were mainly eosinophilic 
(64%) and mixed eosinophilic and neutrophilic (14%). In compar-
ison with class 1, this class was characterized by high sputum 
eosinophilia (median 9.6%). Eosinophilic inflammation was accom-
panied by more severe course of asthma with lower FEV1 values 
(mean 78.8% ±18). Severe asthma was diagnosed in 69%, mild and 
moderate in 31% of study subjects, while no one had intermit-
tent asthma. Asthma remained uncontrolled in 53% of patients, 
mean ACT result was 18.4 ± 4.4. More intense treatment was 
needed, as all subjects received ICS (median 1000 mcg of fluti-
casone daily), and 20% of subjects required oral corticosteroid 
(OCS) treatment. The number of exacerbations (median 1 per year) 
was higher than in class 1. 33% of asthmatics were atopic. LTE4 in 
ISS was significantly higher compared with class 1 (P < .003), but 
lower than in class 3 (P = .019). Concentrations of PGD2 (P = .001), 
PGA2 (P = .007), PGE2 (P = .007), 5-HETE (P = .006), and 11-dehy-
dro-TBX2 (P < .001) were lower than in class 3.
TA B L E  1   Characteristics of the entire NERD cohort
Variable Value
No. of study subjects 95
Female/male subjects, no. (%) 68 (71.6)/27 (28.4)
Age (y), mean ± SD 46.6 ± 12.5
Age at asthma onset (y), mean ± SD 32.6 ± 14.9
Asthma onset > 12 y, no. (%), yes/no 93 (97.9)/2 (2.1)
Duration of asthma (y), median (25th-75th pc) 10 (6-19)
BMI, mean ± SD 26.9 (5.2)
>30 kg/m2, no. (%), yes/no 21 (22.1)/74 (77.9)
ACT mean ± SD 21 ± 4.4
Present level of asthma control (ACT), no. (%)
1: Well controlled 39 (41.1)
2: Partially controlled 35 (36.8)
3: Uncontrolled 21 (22.1)
FEV1 (% predicted), mean ± SD 88.5 ± 16
Exacerbations, median (25th-75th pc) 1 (0-2)
Upper airway symptoms (CRS), no. (%), yes/no 95 (100)/0 (0)
CRS surgery, no. (%), yes/no 66 (69.5)/25 (30.5)
Nasal polyps, no. (%), yes/no 81 (85.3)/14 (14.7)




IgE total, median (25th-75th pc) 102.5 (32.6-216)
Blood eosinophil count, median (25th-75th pc) 389.5 (240-625)
Sputum eosinophilia,%, median (25th-75th pc) 3.7 (0.7-14.6)
Levels of asthma severity, no. (%)
1:Intermittent 9 (9.5)
2:Mild to moderate persistent 48 (50.5)
3:Severe persistent 38 (40)
Treatment of asthma
OCS, no. (%), yes/no 6 (6.3)/89 (93.7)
OCS (mg/d) methylprednisolone, median 
(25th-75th pc)
4 (4-8)
ICS, no. (%), yes/no 86 (90.5)/9 (9.5)
ICS (μg/d) fluticasone, median (25th-75th 
pc)
500 (200-1000)
Abbreviations: ACT, Asthma Control Test; BMI, body mass index; 
CRS, chronic rhinosinusitis; ICS, inhaled corticosteroids; OCS, oral 
corticosteroids.
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Sixteen patients (16.8%) were grouped into class 3, which was 
characterized by asthma with a mild-to-moderate course, relatively 
well controlled, with eosinophilic airway inflammation and increased 
both pro- and anti-inflammatory mediators in induced sputum. This 
group was equally comprised of women and men with a mean age 
of 48.1 ± 12.6y. Obesity was quite frequent in this class (78%). The 
induced sputum specimens were mainly eosinophilic (50%) and 
mixed eosinophilic and neutrophilic (38%). This class was also char-
acterized by high sputum eosinophilia (median 9.2%). No significant 
differences were observed in blood eosinophilia between neither 
classes. The course of asthma was most often mild-to-moderate 
(63%), but with lower FEV1 (89.7% ±14.2%) values compared with 
class 1 (P = .03). Asthma was most frequently partially controlled 
(56%) with mean ACT score 20.6 ± 5. Almost all subjects were 
treated with inhaled corticosteroids (median 320 mcg of fluticasone 
daily). 60% of subjects were atopic, with the highest total serum 
IgE levels. In this class, compared with classes 1 and 2, significantly 
higher concentrations of pro-inflammatory lipid mediators as LTE4 
(P < .001 and P = .019, respectively), PGD2 (P < 001 and P = .01, re-
spectively), 11-dehydro-TBX2, (P < .001 and P < .001, respectively) 
and higher concentration of anti-inflammatory PGE2 (P < .001 and 
P < .001, respectively) were observed. Concentrations of PGA2 
(P = .007) and 5-HETE (P = .006) were higher compared to class 2.
3.1 | Pro- and anti-inflammatory eicosanoids
The between-classes analysis of single mediator concentrations did 
not correlate with asthma severity and disease control; furthermore, 
the concentration of pro- and anti-inflammatory arachidonic acid 
TA B L E  2   Clinical characteristics of the particular classes
Class 1 (n = 43) Class 2 (n = 36) Class 3 (n = 16) P
Female/male subjects, no. (%) 30 (69.8)/13 (29.2) 30 (83.3)/6 (6.7) 3 8 (50)/8 (50) 2 .046
Age (y), mean ± SD 44.7 ± 11.5 48.3 ± 13.5 48.1 ± 12.6 NS
Age at asthma onset (y), mean ± SD 33.2 ± 17.5 30.2 ± 15.2 33.2 ± 13.8 NS
Asthma onset > 12 y, no. (%), yes/no 42 (97.7)/1 (2.3) 36 (100)/0 (0) 15 (93.8)/1 (6.2) NS
Duration of asthma (y), median (25th-75th pc) 7 (5-16) 13 (9-23) 10 (7-21) NS
BMI, mean ± SD 26.3 ± 4 26.4 ± 5.5 29.8 ± 6.4 NS
>30 kg/m2, no. (%), yes/no 5 (11.6)/38 (88.4) 3 9 (33.3)/27 (66.7) 7 (43.8)/9 (56.2)1 .026
ACT mean ± SD 23.4 ± 2.3 2,3 18.4 ± 4.4 1 20.6 ± 5 1 <.001
Present level of asthma control (ACT), no. (%)
1: Well controlled 31 (72.1) 2,3 3 (8.3) 1,3 5 (31.3) 1,2 <.001
2: Partially controlled 12 (27.9) 3 14 (38.9) 9 (56.3)1 <.001
3: Uncontrolled 0 (0) 2,3 19 (52.8) 1,3 2 (12.4) 2,3 <.001
FEV1 (% predicted), mean ± SD 96 ± 9.8 2 78.8 ± 18 1,3 89.7 ± 14.2 1 <.001
Exacerbations, median (25th-75th pc) 0 (0-1)2 1 (1-4)1 0 (0-2) .002
Upper airway symptoms (CRS), no. (%), yes/no 43 (100)/0 (0) 36 (100)/0 (0) 16 (100)/0 (0) NS
CRS surgery, no. (%), yes/no 32 (74.4)/11 (24.6) 26 (72.3)/10 (27.7) 8 (50)/8 (50) NS
Nasal polyps, no. (%), yes/no 35 (81.4)/8 (18.6) 32 (88.9)/4 (11.1) 14 (87.5)/2 (12.5) NS
Positive skin prick test responses, no. (%), yes/no 17 (39.5)/26 (60.5) 12 (33.3)/24 (66.7) 6 (62.5)/10 (32.5) NS
IgE total, median (25th-75th pc) 54.5 (24.1-141) 3 122 (37-318) 194.5 (136-268) 1 .003
Blood eosinophil count, median (25th-75th pc) 373 (240-376) 375 (252-743) 510 (200-612) NS
Sputum eosinophilia, %, median (25th-75th pc) 1.1 (0.4-6.4) 2,3 9.6 (3.6-19.9) 1 9.2 (2.5-20.5) 1 .002
Levels of asthma severity, no. (%)
1: Intermittent 8 (18.6)2 0 1 1 (6.3) <.001
2: Mild-to-moderate persistent 27 (62.8)2 11 (30.6)1,3 10 (62.5)2 <.001
3: Severe persistent 8 (18.6)2 25 (69.4)1,3 5 (31.3) 2 <.001
Treatment of asthma
OCS, no. (%), yes/no 0 (0)/43 (100)2 6 (16.7) 1 0 (0)/16 (100) .048
OCS (mg/d) methylprednisolone, median (25th-75th pc) 0 4 (4-8) 0 <.001
ICS, no. (%), yes/no 35 (81.4)/8 (18.6) 36 (100)/0 (0) 15 (93.8)/1 (6.2) .056
ICS (μg/d) fluticasone, median (25th-75th pc) 250 (100-500)2 1000 (500-1000)1,3 320 (100-500)2 <.001
Abbreviations: ACT, Asthma Control Test; BMI, body mass index; CRS, chronic rhinosinusitis; ICS, inhaled corticosteroids; OCS, oral corticosteroids.
Indices 1-3 show statistical significant difference between two classes (pairwise comparisons).
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metabolites was significantly higher in class 3 than in classes 1 and 2. 
Thus, we looked at the concentrations ratio of pro- and anti-inflamma-
tory mediators that are well known to be important in the pathogenesis 
of NERD2—logLTE4/logPGE2 (Figure2) vs. asthma control and sever-
ity. We found that this ratio differs significantly between class 1 (0.8) 
and classes 2 (1.2) and 3 (1.0), no statistical significance was observed 
between classes 2 and 3. Values of logLTE4/logPGE2 ratio follow the 
clinical course of asthma (Tables 1 and 2). The lowest ratio was found in 
class 1 with good asthma control and milder disease, while the highest 
ratio was observed in class 2 characterized by worse asthma control and 
high grade of asthma severity. In class 3, the value of logLTE4/logPGE2 
ratio was between values calculated for classes 1 and 3, similarly to 
disease control and severity. There was a positive correlation between 
sputum eosinophilia and concentrations of LTE4 (r = 0.58, P < .001) and 
PGD2 (r = 0.38, P = .001) in ISS. LTE4 concentration also correlated posi-
tively with PGD2 concentration measured in ISS (r = 0.47, P < .001). No 
significant correlations were found between PGE2 and both PGD2 and 
LTE4 for the whole NERD group, with a negative correlation between 
LTE4 and PGE2 only in class 2 (r=−0.5, P = .048).
4  | DISCUSSION
The application of latent class analysis revealed three clearly de-
fined classes among the NERD cohort. This grouped together as-
pirin hypersensitive asthmatics according to similarities of specific 
asthma features, induced sputum cell count and lipids mediators 
measured in ISS (each variable is statistically independent). Class 
1 represented well-controlled mild-to-moderate asthma, with low 
sputum eosinophilia, no clear indication for a dominant inflamma-
tion pattern in the bronchial airways and lower concentrations of 
eicosanoids in IS. However, subjects in class 2 had dominantly se-
vere, poorly controlled eosinophilic asthma. High sputum eosino-
philia correlated with the highest concentration of LTE4 in ISS. Class 
3 also represented eosinophilic asthma but with a milder course and 
better lung function. It is interesting that there was no statistical 
difference in logLTE4/logPGE2 ratio when we compared our subjects 
in groups defined only by asthma severity or asthma control (data 
not shown), that is, in the aspect of logLTE4/logPGE2 ratio LCA as-
signed subjects to different groups better than only identification by 








































19.4 (15.2-20,8) 3 31.9 (16.5-22.9)3 41.4 (23.2-89.7)1,2 <.001
Abbreviations: GC-MS, gas chromatography/mass spectrometry; HPLC-MS/MS, high-performance liquid chromatography/tandem mass 
spectrometry; LLOQ, lowest limit of quantification.
Indices 1-3 show statistical significant difference between two classes (pairwise comparisons).
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disease severity or control. Thus, this study presents an approach 
integrating clinical data and laboratory measures of inflammation to 
describe NERD heterogeneity. The LCA was previously applied to 
identify possible NERD subphenotypes in a study by Bochenek et al 
including only urinary LTE4 (uLTE4) as an inflammatory biomarker.
6 
Four classes with disease severity ranging from mild to severe with 
frequent exacerbations and high healthcare utilization were estab-
lished. In this study, the highest levels of uLTE4 among NERD were 
observed among subjects within classes of moderate course, inten-
sive upper airway symptoms, and high blood eosinophil levels. There 
were some similarities and differences to our previous observa-
tions regarding NERD heterogeneity,7 possibly because of the lim-
ited number of subjects taken into analysis not covering all possible 
NERD subphenotypes. Both studies identified two similar groups of 
asthmatics: one with severe disease, impaired lung function, eosino-
philic inflammation and increased LTE4 in ISS and second with mild-
to-moderate asthma, no predominant inflammatory pattern and low 
LTE4 in ISS. The main difference of the present study is identification 
of subgroup of NERD subjects with eosinophilic inflammation, rela-
tively good asthma control, better lung function, and both increased 
pro- and anti-inflammatory mediators in ISS.
NERD is usually described as moderate-to-severe asthma re-
quiring ICS and not rarely systemic corticosteroid to achieve disease 
control.2 We found in this study that patients with the most severe 
course of asthma were grouped together in class 2. It was charac-
terized by lack of asthma control despite high doses of ICS, need for 
OCS, lung function impairment, and a presence of disease exacer-
bations. Therefore, this class resembled the most a typical clinical 
presentation of NERD previously described in literature.2
Asthma is currently thought to consist of multiple phenotypes 
rather than a single disease entity. Asthma phenotypes were ini-
tially focused on combinations of clinical characteristics, but the 
concept evolved to link biology to phenotype, often through a 
statistically based process. This idea of adult asthma phenotypes 
was described by Wenzel in Nature in 2012, grouping asthmatics 
into five phenotypes: early-onset allergic, late-onset eosinophilic, 
exercise-induced, neutrophilic, and obesity-related.23 NERD 
was recognized as a subphenotype of late-onset eosinophilic 
asthma. Persistent eosinophilic inflammation of the airways de-
spite corticosteroid therapy was associated with an adult-onset, 
less frequent allergic sensitization, often with concurrent chronic 
sinusitis, nasal polyps, and sometimes NERD.23-25 Late-onset eo-
sinophilic phenotype was linked with Th2 inflammatory process. 
The cysteinyl leukotriene pathway in NERD is upregulated by Th2 
cytokines, and these potent pro-inflammatory lipid mediators are 
released from cells associated with Th2 inflammation like eosino-
phils, basophils, and mast cells.23,24
The degree of overlap between late-onset eosinophilic asthma 
with NERD and late-onset eosinophilic asthma without NERD is not 
clear. It has also been shown by means of LCA that eosinophilic in-
flammation, intense upper and lower airway symptoms, overproduc-
tion of cysLTs, and PGD2 can characterize both aspirin-tolerant and 
hypersensitive asthma.7
Eosinophilic asthma includes either allergic or nonallergic pheno-
types underlying immune responses mediated by T helper Th2 cell-de-
rived cytokines. Eosinophilic inflammation can be associated with the 
whole spectrum of asthma severity, ranging from mild-to-moderate 
to severe disease and are associated with worse control and disease 
exacerbations.25,26 More severe disease is frequently accompanied by 
mixed patterns of inflammation including both eosinophils and neutro-
phils. Neutrophilic airway inflammation is thought to be triggered by 
Th1 and especially by Th17 lymphocytes. Neutrophils often represent 
the predominant inflammatory cells detected in the induced sputum 
obtained from patients with severely obstructed airways, experienc-
ing uncontrolled symptoms and frequent exacerbations despite high 
intensity of treatment.23,25,27 Additionally, neutrophils generated more 
reactive oxygen species in patients with AERD and in those with severe 
asthma than in those with ATA or nonsevere asthma.28 In this study, all 
inflammatory patterns were seen in the NERD cohort. Classes 2 and 3 
that differed in the course of asthma were characterized by higher spu-
tum eosinophilia. These observations are line with results of studies 
F I G U R E  1   Distribution of inflammatory phenotypes based 
on induced sputum cell count in three latent classes (*-significant 
difference, P < .05 between class)  
F I G U R E  2   LogLTE4/logPGE2 ratio in three latent classes, 
(*-significant difference, P < .05 between class)
838  |     CELEJEWSKA-WÓJCIK Et AL.
including whole asthmatic populations showing eosinophilic asthma to 
be very nonhomogeneous.7,25
The pathogenesis of NERD still remains largely elusive despite 
years of studies. Initiation and persistence of inflammation are 
strongly dependent on type 2 cytokines, eosinophils, mast cells, cys-
LTs, and PGD2. CysLTs like LTE4 that are overproduced in classes 2 
and 3 are strong mediators of allergic inflammation mainly released 
by eosinophils and mast cells.29 In numerous studies, the key role 
of cysLTs overproduction in NERD was well documented on the 
systemic level and increased urinary excretion of LTE4 as a hallmark 
of this disease.2,30 Increased local and systemic biosynthesis of 
pro-inflammatory PGD2 and its metabolites was also found inaspi-
rin hypersensitive asthmatics.12(p2) PGE2 plays a protective role in 
the lungs. It exerts a bronchodilatory effect through a direct effect 
on the smooth muscle of the bronchi, but also has anti-inflamma-
tory activity, reducing the release of mediators by mast cells and 
eosinophils.31 In class 2 concentration of bronchoprotective PGE2 
in ISS was the lowest, which could possibly explain the worse lung 
function, severe course of the disease and frequent exacerbations, 
whereas class 3 was characterized by the highest concentration of 
PGE2 in ISS. The milder course of asthma in this class despite eosin-
ophilic inflammation and increased concentration of pro-inflamma-
tory mediators could possibly be explained by the rescue effect of 
this prostanoid on airways.
We also analyzed the ratio of logLTE4/logPGE2 mediators between 
classes to look for the best parameter describing clinical course and 
because the concentration of pro- and anti-inflammatory arachidonic 
acid metabolites in class 3 was significantly higher than in classes 1 
and 2. Statistical analysis of this ratio revealed significant differences 
between class 1 vs classes 2 and 3—consistent with asthma control 
and severity in classes, showing that the overbalance of PGE2 vs. LTE4 
influences the disease course in classes defined by LCA.
Most studies in NERD have shown a cytokine profile con-
sistent with type 2 immunity; however, some studies suggest a 
possible role for Th1 response and IFN-γ as well.32,33 Both IL-4 
and IFN-γ increase LTC4 synthase expression on mast cells and 
eosinophils, providing a link for the upregulation of CysLTs seen 
in NERD.34 Eosinophils and mast cells expressing 5-LO and LTC4 
synthase are the main source of cysLTs in hypersensitivity reac-
tions, yet platelets may also play a role in cysLTs overproduction. 
Platelet-leukocyte aggregates were found in higher concentra-
tions in blood and upper airway tissue from NERD patients reflect-
ing systemic overproduction of cysLTs measured by urinary LTE4.
16 
Other important cells in NSAIDs provoked reactions are the ILC2s 
present in lower and upper airways.35-37 ILC2s activation is de-
pendent on local respiratory epithelium damage and results in the 
generation of pro-inflammatory cytokines and enhancement of 
upper and lower inflammation, mucus production, bronchocon-
striction and remodeling. It was shown that ILC2s are recruited 
to nasal mucosa of NERD patients after COX-1 inhibitor admin-
istration, correlating with enhanced production of prostaglandins 
and leukotrienes.15,38 Concurrently, ILC2s activate and recruit 
mast cells and eosinophils39 by production of cytokines such as 
IL-5 and IL-9 but in a response to released PGD2 and cysLTs ILC2s 
are activated. These observations show how complex the patho-
genesis of aspirin exacerbated disease is, including not only the al-
ternations in eicosanoid production after COX-1 inhibition. In our 
study, we have two eosinophilic asthma classes but differing in 
clinical course and concentrations of eicosanoids measured in ISS. 
It is possible that more than one pathway in NERD depending on 
the local environment can lead to eosinophilic inflammation with 
a different eicosanoid profile, reflecting the heterogeneity of this 
asthma phenotype.
In our study, LCA revealed subphenotypes within NERD cohort, 
which is by itself regarded as a distinct asthma phenotype. We used 
a model based on 16 variables including clinical data, inflammatory 
cell count, and eicosanoids measured in ISS to address different as-
pects of the disease including underlying biochemical processes. 
The model with three latent classes was selected as the best one 
fitting the analyzed data basing on AIC. Furthermore, the high values 
of posterior probability indicated that participants were assigned to 
classes in an unambiguous manner.
We are aware of limitations of our study. It might be questioned 
if such a stratification of the NERD cohort into classes is a realis-
tic approach. The distribution of patients may change depending on 
population size and selected variables. It is known that inflammatory 
patterns of influx cells in the airways may change over time, as many 
factors such as administration of corticosteroids or exposition to 
allergens influence the composition of influx cells40-42 on inflamma-
tory cell subtypes in asthma.
It must be stated that the stability of subphenotypes over time 
has not been analyzed.
More data from recent studies support the idea of a more com-
plex pathogenesis of NERD. Our experience with NERD patients 
suggests the need to reconsider NSAID hypersensitive asthma 
in means of subphenotypes requiring a different therapeutical 
approach.
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